Management of the thrombotic lesion: Difference between revisions
Jump to navigation
Jump to search
New page: {{SI}} {{WikiDoc Cardiology Network Infobox}} {{CMG}}<br/> '''Associate Editors-In-Chief:''' ==Goals of Treatment== There are several main goals in treating thrombotic lesions, including:... |
No edit summary |
||
Line 13: | Line 13: | ||
==Treatment Choices== | ==Treatment Choices== | ||
===Pharmacologic Therapy=== | ===Pharmacologic Therapy=== | ||
*Antiplatelet therapy: Aspirin, platelet glycoprotein IIb/IIIa receptor (GP IIb/IIIa) antagonists (abciximab, eptifibatide, tirofiban), ADP receptor/P2Y12 inhibitors (plavix, ticagrelor, prasugrel) | |||
*Antithrombin Therapy: Ufractionated heparin (UFH), low molecular weight heparin (LMWH). Fondaparinux not recommended in primary PCI. | |||
*Direct Thrombin Inhibitors: hirudin, bivalirudin, argatroban | |||
*Thrombolytic Therapy: Urokinase (UK), tissue plasminogen activator (tPA) for STEMI when other pharmacologic and mechanical treatments are not successful | |||
===Mechanical Therapy=== | ===Mechanical Therapy=== | ||
*Aspiration Catheter: (Export, Pronto) is the choice prior to the other interventions listed below | |||
*Percutaneous Coronary Intervention (PCI): Bare metal or drug-eluting stent particularly direct stenting without pre-dilation by conventional balloon angioplasty | |||
*Distal Protection: (Percusurge guardwire, Triactive, Spider wire, Proxis) particularly in saphenous vein grafts | |||
*Percutaneous Transluminal Coronary Angioplasty (PTCA) | |||
*Directional Atherectomy | |||
*Transluminal Extraction Catheter (TEC) | |||
*Rheolytic Thrombectomy (Possis Angiojet) | |||
{{SIB}} | {{SIB}} |
Revision as of 13:45, 6 August 2010
Cardiology Network |
Discuss Management of the thrombotic lesion further in the WikiDoc Cardiology Network |
Adult Congenital |
---|
Biomarkers |
Cardiac Rehabilitation |
Congestive Heart Failure |
CT Angiography |
Echocardiography |
Electrophysiology |
Cardiology General |
Genetics |
Health Economics |
Hypertension |
Interventional Cardiology |
MRI |
Nuclear Cardiology |
Peripheral Arterial Disease |
Prevention |
Public Policy |
Pulmonary Embolism |
Stable Angina |
Valvular Heart Disease |
Vascular Medicine |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Associate Editors-In-Chief:
Goals of Treatment
There are several main goals in treating thrombotic lesions, including:
- Reperfusion of the epicardial artery and the downstream microvasculature
- Resolution/reduction of [[thrombus burden
- Avoid/minimize distal embolization
- Avoid/reduce thrombotic major adverse cardiac events (death, MI, recurrent ischemia, urgent target vessel revascularization (TVR))
Treatment Choices
Pharmacologic Therapy
- Antiplatelet therapy: Aspirin, platelet glycoprotein IIb/IIIa receptor (GP IIb/IIIa) antagonists (abciximab, eptifibatide, tirofiban), ADP receptor/P2Y12 inhibitors (plavix, ticagrelor, prasugrel)
- Antithrombin Therapy: Ufractionated heparin (UFH), low molecular weight heparin (LMWH). Fondaparinux not recommended in primary PCI.
- Direct Thrombin Inhibitors: hirudin, bivalirudin, argatroban
- Thrombolytic Therapy: Urokinase (UK), tissue plasminogen activator (tPA) for STEMI when other pharmacologic and mechanical treatments are not successful
Mechanical Therapy
- Aspiration Catheter: (Export, Pronto) is the choice prior to the other interventions listed below
- Percutaneous Coronary Intervention (PCI): Bare metal or drug-eluting stent particularly direct stenting without pre-dilation by conventional balloon angioplasty
- Distal Protection: (Percusurge guardwire, Triactive, Spider wire, Proxis) particularly in saphenous vein grafts
- Percutaneous Transluminal Coronary Angioplasty (PTCA)
- Directional Atherectomy
- Transluminal Extraction Catheter (TEC)
- Rheolytic Thrombectomy (Possis Angiojet)